Fig. 5

Antitumor efficacy in vitro and vivo. A Cell viability of HepG2&LX-2 mixed 3D tumor spheres treated with various formulations. Data are represented as mean ± SD, n = 3, **P < 0.01. B Area of 3D tumor spheres after treatments with various formulations. Data are represented as mean ± SD, n = 6, **P < 0.01. C Bright field images and H&E staining of the 3D tumor spheres treated with various formulations. Scale bar: 100 μm. D Scheme of combinational therapy of CFH/OM-L and IC-ML. E Ex vivo tumors of mice at the end of various treatments. F Curve of the tumor growth during the treatments. Data are represented as mean ± SD, n = 5. Compared with the saline group, **P < 0.01, ***P < 0.001; compared with IC-ML group, ^###P < 0.001; compared with CFH/OM-L group, ^{^^^}P < 0.001. G Tumor inhibition rate of each group. Data are represented as mean ± SD, n = 5. *P < 0.05. H Tumor weight of each group at the end of the treatments. Data are represented as mean ± SD, n = 5. *P < 0.05. I Survival curves of tumor-bearing mice during and after the treatments. Data are represented as mean ± SD, n = 8. Compared with the saline group, *P < 0.05. J H&E, Ki67, and TUNEL staining of tumor sections in each group